Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. (Q51292373)
Jump to navigation
Jump to search
scientific article published on 17 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. |
scientific article published on 17 December 2015 |
Statements
1 reference
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. (English)
1 reference
Christof M Kazda
1 reference
Ying Ding
1 reference
Ronan P Kelly
1 reference
Parag Garhyan
1 reference
Chunxue Shi
1 reference
Chay Ngee Lim
1 reference
Haoda Fu
1 reference
David E Watson
1 reference
Andrew J Lewin
1 reference
William H Landschulz
1 reference
Mark A Deeg
1 reference
David E Moller
1 reference
Thomas A Hardy
1 reference
17 December 2015
1 reference
1 reference
39
1 reference
7
1 reference
1241-1249
1 reference
Identifiers
1 reference
1 reference